Localized Scleroderma / Morphea (Investigational Adjunct)
Highly investigational adjunct for stable plaque morphea; no RCT evidence; UVA1 phototherapy and methotrexate remain primary for active disease.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for morphea (localized scleroderma). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- ¿Qué evidencia existe?
- Tier C (investigational). No controlled trials. Evidence-based first-line management of active morphea is topical or intralesional corticosteroid for limited plaques, calcipotriene-betamethasone for superficial disease, narrowband UVB or UVA1 phototherapy for widespread plaques, and methotrexate plus systemic corticosteroid for severe or rapidly progressive disease in pediatric and adult patients.
- Riesgos principales
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Worsening of skin sclerosis (theoretical) from inflammatory bite sites
- Permanent dyspigmentation in already pigmented or hypopigmented plaques
- Quién no debería considerar esto
- Patients with active inflammatory morphea who have not had a trial of phototherapy or methotrexate
- Patients with linear or deep morphea affecting joint mobility (need rheumatology workup)
- Children with pansclerotic or coup-de-sabre variants (need aggressive systemic therapy)
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Qué preguntar a su clínico
- Has my morphea subtype (plaque, linear, generalized, deep) been correctly classified by dermatology or rheumatology?
- Have I tried phototherapy (UVA1 or narrowband UVB)?
- Should methotrexate plus systemic steroid be tried for active disease?
- What is the published evidence base for leeches in morphea specifically?
- What is the risk of pigment changes or bite scarring on top of existing morphea?
- How will disease activity be monitored — clinical, ultrasound, both?
- Cuándo buscar atención urgente
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Rapid expansion of a plaque, new joint contracture, or limb-length discrepancy (in children)
- New neurologic symptoms with coup-de-sabre lesions (rare but reported)
Qué NO significa esto
- It does not mean leech therapy is FDA-cleared for morphea — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace phototherapy, methotrexate, or systemic corticosteroid for active disease.
- It does not stop the underlying fibrosing process driving morphea.
- It does not address functional or growth complications in pediatric linear or deep morphea.
- It does not have controlled-trial evidence in any morphea subtype.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- dermatological
- ICD-10
- L94.0, L94.1
- Safety tier
- medium
Evidence Summary
Localized scleroderma (morphea) is an autoimmune fibrosing disorder of skin and subcutaneous tissue. Active disease is treated per AAD and EUSCLE guidance with methotrexate (often with systemic corticosteroid bridge), UVA1 or narrowband UVB phototherapy, and topical calcipotriene plus high-potency steroid. A small uncontrolled Azerbaijan center series (Farzali 2025) reported 100 percent self- and physician-rated improvement in n=2 scleroderma patients receiving hirudotherapy, but the sample size, lack of blinding, and absence of objective sclerometric outcomes preclude conclusions about disease modification. Proposed mechanism centers on dampening dermal fibrogenic signaling via salivary peptides. No high-quality evidence supports use for active or extensive morphea.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Farzali S et al. (2025), n=2 · PMID 40923484 · ASH analysis →
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active morphea (violaceous border, peripheral erythema, expansion)
- Linear morphea en coup de sabre or pansclerotic morphea
- Generalized morphea with systemic features
- Pediatric morphea (refer to pediatric rheumatology)
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.